A CRA expert provided input to the Canadian Competition Bureau in its evaluation of the proposed merger of two branded pharmaceutical manufacturers. CRA’s team considered the ability and incentive of the merging parties to increase the price of a branded pharmaceutical following the merger. Aspects of this consideration included setting out the features of list and net pricing of branded drugs in the Canadian pharmaceutical marketplace, and the various constraints and factors that bear on those prices.
Lexology Index recognizes 44 CRA competition experts globally
This year, 44 CRA experts were named among the leading Competition Economists, with four recognized as Competition Future Leaders – Economists. This...